#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal cancer Lymphatic malformation Medulloblastoma recurrent Adrenocortical carcinoma Systemic mastocytosis PIK3CA-activated mutation Deafness Essential thrombocythaemia Fibrosarcoma metastatic Autoimmune myositis Gaucher's disease type III Palmoplantar pustulosis Myasthenia gravis Blood iron increased Neovascular age-related macular degeneration More trials…

    Learn about Rare Diseases

    Hypereosinophilic syndrome – Trials in Disease Behcet’s syndrome – Basic Information Langerhans cell sarcoma – Diagnostics Myxofibrosarcoma – Treatment Glomerulonephritis membranous – Treatment Rett syndrome – Treatment Cystic fibrosis – Basic Information Gaucher’s disease type I – Life with Disease Nodal marginal zone B-cell lymphoma Haemophilia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Icosapent Ethyl Artemisia Vulgaris (312) Bisoprolol Fumarate Nafarelin Neomycin Sulfate Ciclesonide Mva-209-Fsp-B3 Dirocaftor GUAIACOL Clemizole Hydrochloride Dydrogesterone Palivizumab Tomligisiran FERUMOXTRAN-10 Sapablursen Aprepitant Naltrexone Hydrochloride IPN01195 Eye103 Terbinafine More therapies…

    Learn about Your Condition

    Rectal cancer stage III Alcoholic liver disease Cervix carcinoma stage IV Fragile X syndrome Indolent systemic mastocytosis Neoplasm Dent's disease Testicular leiomyosarcoma Urticaria Hepatic neoplasm Metastases to peritoneum Ischaemic stroke Thalassaemia alpha Lymphocytic leukaemia Inguinal hernia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Follicular lymphoma

  • Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    France Greece Spain

  • Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Loncastuximab Tesirine
    • Epcoritamab
    Germany

  • Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    • T-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Placebo
    Denmark

  • Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Pegfilgrastim
    • Golcadomide
    • Bendamustine Hydrochloride
    Finland France Germany Greece Italy The Netherlands +2

  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    • Primary amyloidosis
    • Malignant melanoma
    Investigated Drugs:
    • Atezolizumab
    • Cemiplimab
    • Daratumumab
    France

  • Study on Rituximab, Lenalidomide, and Tafasitamab for Treating High-Risk and Low-Risk Follicular Lymphoma Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Tafasitamab
    • Lenalidomide
    • Rituximab
    Denmark Finland Iceland Norway Sweden
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!